CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Cash flows from operating activities:
Net income (loss)	$ (2,483)	$ 32,779	$ 135,817
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	99,886	69,103	6,984
Impairment of intangible assets	19,663	0	0
Provision for bad debt expense	3,209	0	0
Amortization of premium/discount on purchased securities	624	2,152	2,080
Write-down of inventory to net realizable value	0	1,235	1,309
Gain (loss) on disposal of property and equipment	0	0	(103)
Non-cash equity-based compensation expense	22,543	17,237	8,625
Non-cash loss on debt extinguishment	0	6,426	0
Amortization of debt discount and debt issuance costs	12,105	11,379	6,870
Gains on investments, net	38	(14)	(114)
Change in fair value of contingent consideration	25,683	4,271	(681)
Deferred income taxes	7,279	5,007	(153,159)
Changes in operating assets and liabilities:
Accounts receivable, net	(9,906)	(36,913)	3,588
Inventories	(2,355)	(5,237)	(1,360)
Receivable from collaboration	428	4,090	(4,239)
Prepaid and other current assets	4,095	4,034	2,331
Accounts payable and accrued expenses	49,037	7,876	10,694
Deferred revenues	24,522	(22,197)	(8,384)
Payment of contingent consideration in excess of acquisition date fair value	(8,116)	0	0
Repayment of term loan attributable to original issue discount	0	(12,491)	0
Other assets and liabilities	(30)	7,244	1,156
Net cash provided by operating activities	246,222	95,981	11,414
Cash flows from investing activities:
Acquisition of Lumara Health, net of acquired cash	0	562	(595,602)
Acquisition of CBR, net	0	(682,356)	0
Proceeds from sales or maturities of investments	127,479	208,966	223,568
Purchase of investments	(194,723)	(424,759)	(63,747)
Change in restricted cash	0	(195)	2,883
Capital expenditures	(5,460)	(1,259)	(44)
Net cash used in investing activities	(72,704)	(899,041)	(432,942)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses	0	407,477	0
Long-term debt principal payments	(17,502)	(327,509)	0
Proceeds from long-term debt	0	834,750	527,509
Payment of debt issuance costs	0	(10,004)	(7,760)
Proceeds from issuance of warrants	0	0	25,620
Purchase of convertible bond hedges	0	0	(39,760)
Payment of contingent consideration	(92,130)	(456)	(270)
Payment to former CBR shareholders	0	(7,195)	0
Payments for repurchases of common stock	(20,000)	0	0
Proceeds from the exercise of stock options	1,468	15,406	8,499
Proceeds from the issuance of common stock under ESPP	2,417	0	0
Payments of employee tax withholding related to equity-based compensation	(2,171)	0	0
Net cash (used in) provided by financing activities	(127,918)	912,469	513,838
Net increase in cash and cash equivalents	45,600	109,409	92,310
Cash and cash equivalents at beginning of the year	228,705	119,296	26,986
Cash and cash equivalents at end of the year	274,305	228,705	119,296
Supplemental data of cash flow information:
Cash paid for taxes	5,309	2,373	0
Cash paid for interest	62,381	28,014	2,500
Non-cash investing activities:
Fair value of acquisition-related contingent consideration	0	0	205,000
Fair value of common stock issued in connection with the Lumara Health acquisition	$ 0	$ 0	$ 111,964